- Home
- SCOR vs AKTX Comparison
SCOR vs AKTX Comparison
Compare SCOR & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCOR
- AKTX
- Stock Information
- Founded
- SCOR 1999
- AKTX N/A
- Country
- SCOR United States
- AKTX United States
- Employees
- SCOR N/A
- AKTX N/A
- Industry
- SCOR Business Services
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- SCOR Consumer Discretionary
- AKTX Health Care
- Exchange
- SCOR Nasdaq
- AKTX Nasdaq
- Market Cap
- SCOR 34.6M
- AKTX 35.7M
- IPO Year
- SCOR 2007
- AKTX N/A
- Fundamental
- Price
- SCOR $6.80
- AKTX $0.78
- Analyst Decision
- SCOR
- AKTX Strong Buy
- Analyst Count
- SCOR 0
- AKTX 2
- Target Price
- SCOR N/A
- AKTX $3.30
- AVG Volume (30 Days)
- SCOR 7.8K
- AKTX 91.9K
- Earning Date
- SCOR 11-11-2025
- AKTX 08-13-2025
- Dividend Yield
- SCOR N/A
- AKTX N/A
- EPS Growth
- SCOR N/A
- AKTX N/A
- EPS
- SCOR N/A
- AKTX N/A
- Revenue
- SCOR $358,513,000.00
- AKTX N/A
- Revenue This Year
- SCOR $3.45
- AKTX N/A
- Revenue Next Year
- SCOR $2.59
- AKTX N/A
- P/E Ratio
- SCOR N/A
- AKTX N/A
- Revenue Growth
- SCOR N/A
- AKTX N/A
- 52 Week Low
- SCOR $4.39
- AKTX $0.57
- 52 Week High
- SCOR $8.99
- AKTX $3.85
- Technical
- Relative Strength Index (RSI)
- SCOR 58.42
- AKTX 39.38
- Support Level
- SCOR $6.30
- AKTX $0.75
- Resistance Level
- SCOR $6.50
- AKTX $0.89
- Average True Range (ATR)
- SCOR 0.16
- AKTX 0.07
- MACD
- SCOR -0.04
- AKTX 0.01
- Stochastic Oscillator
- SCOR 76.39
- AKTX 64.42
About SCOR comScore Inc.
comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each across media platforms. The platforms it measures include televisions, mobile devices, computers, tablets, CTV devices, and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada, and other regions. It provides solutions for the automotive, digital media, financial services, pharmaceutical, retail, technology, travel, and other industries.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.